Рецидивирующее течение поствоспалительной кардиопатии: уроки прошлых эпидемий

Вирусы являются самым частым этиологическим агентом воспалительного поражения миокарда. На сегодня коронавирус тяжелого острого респираторного синдрома (SARS-CoV-2) обусловливает высокую частоту миокардита и перикардита, что поднимает вопросы о механизмах его кардиотропности и отдаленных последствиях воспаления. В качестве предположительного сценария мы представляем клинический случай пациента, перенесшего вирусный миокардит на фоне «атипичной пневмонии» 2004 г, с рецидивами воспаления сердечной мышцы при последующих острых респираторных вирусных инфекциях, последняя из которых была инициирована SARS-CoV-2.

Выполнен анализ литературы, включающий описанные случаи воспаления миокарда на фоне предшественников штамма SARS-CoV-2: SARS-CoV-1 и MERS. Также проведен обзор имеющихся данных по диагностике вирусного миокардита в реалиях настоящей пандемии, который демонстрирует большую неоднородность выявления признаков воспаления сердечной мышцы по результатам разных методов исследования и по данным разных специалистов внутри одной методики, что ставит вопросы о необходимости пересмотра традиционных критериев миокардита в случае с COVID-19.

миокардит, поствоспалительная кардиопатия, диагностика, прогноз, COVID-19

1. Ammirati E., Frigerio M., Adler E.D. et al. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. An Expert Consensus Document. Circulation: Heart Failure. 2020;13:e007405. DOI: 10.1161/CIRCHEARTFAILURE.120.007405

2. Coronavirus never before seen in humans is the cause of SARS. United Nations World Health Organization. 2006-04-16. Retrieved 2006-07-05.

3. Cherry J.D. The chronology of the 2002-2003 SARS mini pandemic. Paediatr. Respir. Rev. 2004;5(4):262–9. DOI: 10.1016/j.prrv.2004.07.009

4. Sørensen M.D., Sørensen B., Gonzalez-Dosal R. et al. Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals. Ann. N.-Y. Acad. Sci. 2006;1067(1):500–505. DOI: 10.1196/annals.1354.072

5. World Health Organization. URL: https://applications.emro.who.int/docs/EMROPub-MERS-SEP-2019-EN.pdf?ua=1&ua=1

6. Assiri A., McGeer A., Trish M. et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 2013;369:407–16. DOI: 10.1056/NEJMoa1306742

7. Alexander L.K., Keene B.W., Small J.D. et al. Electrocardiographic changes following rabbit coronavirus-induced myocarditis and dilated cardiomyopathy. Adv. Exp. Med. Biol. 1993;342:365–370. DOI: 10.1007/978-1-4615-2996-5_56

8. Oh M.D., Park W.B., Park S.W. et al. Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea. Korean J. Intern. Med. 2018;33(2):233–246. DOI: 10.3904/kjim.2018.031

9. Zhang A.R., Shi W.Q., Liu K. et al. Epidemiology and evolution of Middle East respiratory syndrome coronavirus, 2012–2020. Infect. Dis. Poverty. 2021;10:66. DOI: 10.1186/s40249-021-00853-0

10. McIntosh K., Perlman S. Coronaviruses, Including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Mandell, Douglas, and Bennett's. Principles and Practice of Infectious Diseases. 2015;1928–1936.e2. DOI: 10.1016/B978-1-4557-4801-3.00157-0

11. Wu Z. and McGoogan J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;2648. DOI: 10.1001/jama.2020.2648

12. Moldofsky H., Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11:37. DOI: 10.1186/1471-2377-11-37

13. Yu C.M., Wong R.S., Wu E.B. et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad. Med. J. 2006;82(964):140–4. DOI: 10.1136/pgmj.2005.037515

14. Li S.S., Cheng C.W., Fu C.L. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation. 2003;108(15):1798–1803. DOI: 10.1161/01.CIR.0000094737.21775.32

15. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann. Saudi Med. 2016;36:78–80. DOI: 10.5144/0256-4947.2016.78

16. Huang C.H., Vallejo J.G., Kollias G. & Mann D.L. Role of the innate immune system in acute viral myocarditis. Basic. Res. Cardiol. 2009;104:228–237. DOI: 10.1007/s00395-008-0765-5

17. Heymans S., Eriksson U., Lehtonen J. & Cooper, L.T.Jr. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J. Am. Coll. Cardiol. 2016;68:2348–2364. DOI: 10.1016/j.jacc.2016.09.937

18. Muller I. et al. Serum alarmin S100A8/S100A9 levels and its potential role as biomarker in myocarditis. ESC Heart Fail. 2020;7:1442–1451. DOI: 10.1002/ehf2.12760

19. Malkiel S., Kuan A.P., Diamond B. Autoimmunity in heart disease: mechanisms and genetic susceptibility. Mol. Med. Today. 1996;2:336–342. DOI: 10.1016/1357-4310(96)81799-0

20. Huber S.A., Gauntt C.J., Sakkinen P. Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Adv. Virus. Res. 1998;51:35–80. DOI: 10.1016/S0065-3527(08)60783-6

21. Klingel K., Hohenadl C, Canu A. et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc. Natl. Acad. Sci. USA 1992;89:314–318. DOI: 10.1073/pnas.89.1.314

22. Caraffa R., Marcolongo R., Bottio T. et al. Recurrent autoimmune myocarditis in a young woman during the coronavirus disease 2019 pandemic. ESC Heart Fail. 2021Feb;8(1):756–760. DOI: 10.1002/ehf2.13028

23. Caforio A.L. et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur. Heart J. 2007;28: 1326–1333. DOI: 10.1093/eurheartj/ehm076

24. Tschöpe C., Ammirati E., Bozkurt B. et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat. Rev. Cardiol. 2021;18(3):169–193. DOI: 10.1038/s41569-020-00435-x

25. Li Y., Heuser J.S, Cunningham L.C., et al. Mimicry and anti-body-mediated cell signaling in autoimmune myocarditis. J. Immunol. 2006;177:8234–8240. DOI: 10.4049/jimmunol.177.11.8234

26. Alexander L.K., Small J.D, Edwards S. and Baric R.S. An experimental model for dilated cardiomyopathy after rabbit coronavirus infection. J. Infect. Dis. 1992;166:978–85. DOI: 10.1093/infdis/166.5.978

27. Platz E., Jhund P.S., Claggett B.L. et al. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. Eur. J. Heart Fail. 2018;20:295–303. DOI: 10.1002/ejhf.901

28. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 28;395(10229):1054–1062. DOI: 10.1016/S0140-6736(20)30566-3

29. Wang D., Hu B., Hu C. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. DOI: 10.1001/jama.2020.1585

30. Lala A., Johnson K.W., Januzzi J.L. et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J. Am. Coll. Cardiol. 2020;76:533–546. DOI: 10.1016/j.jacc.2020.06.007

31. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. DOI: 10.1016/S0140-6736(20)30183-5

32. Irabien-Ortiz Á., Carreras-Mora J., Sionis A. et al. Fulminant myocarditis due to COVID-19. Rev. Esp. Cardiol. 2020;73:503–504. DOI: 10.1016/j.recesp.2020.04.001

33. Paul J-F., Charles P., Richaud C. et al. Myocarditis revealing COVID-19 infection in a young patient. Eur. Heart J. Cardiovasc. Imaging. 2020;21:776. DOI: 10.1093/ehjci/jeaa107

34. Tomasoni D., Italia L., Adamo M. et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur. J. Heart. Fail. 2020;22(6):957–966. DOI: 10.1002/ejhf.1871

35. Shi S., Qin M., Shen B. et al. Cardiac injury in patients with corona virus disease 2019. JAMA Cardiol. 2020;5(7):802–810. DOI: 10.1001/jamacardio.2020.0950

36. Guo T., Fan Y., Chen M. et al. Association of cardiovascular disease and myocardial injury with outcomes of patients hospitalized with 2019-coronavirus disease (COVID-19). JAMA Cardiol. 2020;1017. DOI: 10.1001/jamacardio.2020.1017

37. Madjid M., Safavi-Naeini P., Solomon S.D., Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020;5(7):831–840. DOI: 10.1001/jamacardio.2020.1286

38. Atri D., Siddiqi H.K., Lang J.P. et al. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. JACC Basic to Transl. Sci. 2020;5:518–536. DOI: 10.1016/j.jacbts.2020.04.002

39. Akhmerov A., Marbán E. COVID-19 and the Heart. Circ. Res. 2020;126:1443–1455. DOI: 10.1161/CIRCRESAHA.120.317055

40. Pericàs J.M., Hernandez-Meneses M., Sheahan T.P. et al. COVID-19: from epidemiology to treatment. Eur. Heart J. 2020;41:2092–2112. DOI: 10.1093/eurheartj/ehaa462

41. Tersalvi G., Vicenzi M., Calabretta D. et al. Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms. J. Card. Fail. 2020;26:470–475. DOI: 10.1016/j.cardfail.2020.04.009

42. Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418. DOI: 10.1016/S0140-6736(20)30937-5

43. Caforio A.L.P., Pankuweit S., Arbustini E. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2013;34:2636–2648. DOI: 10.1093/eurheartj/eht210

44. Lindner D., Fitzek A., Bräuninger H. et al. Association of Cardiac Infection With SARS-CoV-2 in Confi rmed COVID-19 Autopsy Cases. JAMA Cardiol. 2020;5:1281–1285. DOI: 10.1001/jamacardio.2020.3551

45. Xu Z., Shi L., Wang Y. et al. Pathological fi ndings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8(4):420-422. DOI: 10.1016/S2213-2600(20)30076-X

46. Kawakami R., Sakamoto A., Kawai K. et al. Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 2021;77(3):314–325. DOI: 10.1016/j.jacc.2020.11.031

47. Zhou R. Does SARS-CoV-2 cause viral myocarditis in COVID-19 patients? Eur. Heart J. 2020;41(22):2123. DOI: 10.1093/eurheartj/ehaa392

48. Kim I.C., Kim J.Y., Kim H.A. and Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur. Heart J. 2020;41(19):1859. DOI: 10.1093/eurheartj/ehaa288

49. Sala S., Peretto G., Gramegna M. et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur. Heart J. 2020;41(19):1861–1862. DOI: 10.1093/eurheartj/ehaa286

50. Oudit G.Y., Kassiri Z., Jiang C. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Invest. 2009;39(7):618–625. DOI: 10.1111/j.1365-2362.2009.02153

51. Peretto G., Sala S. and Caforio A.L.P. Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associated myocardial involvement. Eur. Heart J. 2020;41(22):2124–2125. DOI: 10.1093/eurheartj/ehaa396

52. Dong N., Cai J., Zhou Y. et al. End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV. JACC Heart Fail. 2020;8(6):515–517. DOI: 10.1016/j.jchf.2020.04.001

53. Inciardi R.M., Lupi L., Zaccone G. et al. Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020Jul1;5(7):819–824. DOI: 10.1001/jamacardio.2020.1096

54. Tavazzi G., Pellegrini C., Maurelli M. et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur. J. Heart Fail. 2020;22(5):911–915. DOI: 10.1002/ejhf.1828

55. Zeng J.H., Liu Y.X., Yuan J. et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020;48(5):773–777. DOI: 10.1007/s15010-020-01424-5

56. Libby P., Nahrendorf M., Swirski F.K. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease: an expanded “cardiovascular continuum” J. Am. Coll. Cardiol. 2016;67:1091–1103. DOI: 10.1016/j.jacc.2015.12.048

57. Guan W., Ni Z., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. DOI: 10.1056/NEJMoa2002032

58. Pan Y., Zhang D., Yang P. et al. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect. Dis. 2020;20:411–412. DOI: 10.1016/S1473-3099(20)30113-4

59. Cao X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020;20:269–270. DOI: 10.1038/s41577-020-0308-3

60. Feldstein L.R., Rose E.B., Horwitz S.M. et al. Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 2020;383:334–346. DOI: 10.1056/NEJMoa2021680

61. Zhao X., Nicholls J.M., Chen Y.G. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor?beta signaling. J. Biol. Chem. 2008;283:3272–80. DOI: 10.1074/jbc.M708033200

62. Puntmann V.O., Carerj M.L., Wieters I. et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–1273. DOI: 10.1001/jamacardio.2020.3557

63. Clark D.E., Parikh A., Dendy J.M. et al. COVID?19 Myocardial Pathology Evaluation in AthleTEs with Cardiac Magnetic Resonance (COMPETE CMR). Circulation. 2021;143(6):609–612. DOI: 10.1161/CIRCULATIONAHA.120.052573

64. Małek Ł.A., Marczak M., Miłosz-Wieczorek B. et al. Cardiac involvement in consecutive elite athletes recovered from Covid-19: A magnetic resonance study. J. Magn. Reson. Imaging. 2021;53(6):1723–1729. DOI: 10.1002/jmri.27513

65. Huang L., Zhao P., Tang D. et al. Cardiac involvement in patients recovered from COVID-2019 identifi ed using magnetic resonance imaging. JACC Cardiovasc. Imaging. 2020;13:2330–9. DOI: 10.1016/j.jcmg.2020.05.004

66. Сукмарова З.Н., Потапов Е.В., Овчинников Ю.В., Саидова М.А., Громов А.И. Ультразвуковые находки и сопоставления изменений перикарда у пациентов, перенесших COVID-19: проспективное исследование. Ультразвуковая и функциональная диагностика. 2021; 4.

67. Furqan M.M., Verma B.R., Cremer P.C., Imazio M., Klein A.L. Pericardial Diseases in COVID19: a Contemporary Review. Curr. Cardiol. Rep. 2021;23(7)90. DOI: 10.1007/s11886-021-01519-x

68. Siripanthong B., Nazarian S., Muser D. et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020;17(9):1463–1471. DOI: 10.1016/j.hrthm.2020.05.001

69. Kotecha T., Knight D.S., Razvi Y. et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur. Heart J. 2021;42(19):1866–1878. DOI: 10.1093/eurheartj/ehab075

70. Moulson N., Petek B.J., Drezner J.A. SARS-CoV-2 cardiac involvement in young competitive athletes. Circulation. 2021;144:256–266. DOI: 10.1161/CIRCULATIONAHA.121.054824

71. Lavie C.J., Sanchis-Gomar F., Lippi G. Cardiac injury in COVID-19-echoing prognostication. J. Am. Coll. Cardiol. 2020;76(18):2056–9 PMID: 33121711. DOI: 10.1016/j.jacc.2020.08.068

72. Szekely Y., Lichter Y., Taieb P. et al. Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study. Circulation. 2020;142(4):342–53. DOI: 10.1161/CIRCULATIONAHA.120.047971

73. Cooper L.T. Myocarditis. N. Engl. J. Med. 2009;360:1526–1538. DOI: 10.1056/NEJMra0800028.

74. Remes J., Helin M., Vaino P., Rautio P. Clinical outcome and left ventricular function 23 years after acute coxsackie virus myopericarditis. Eur. Heart J. 1990;11:182–188. DOI: 10.1093/oxfordjournals.eurheartj.a059675

75. Peters N.S., Poole-Wilson P.A. Myocarditiscontinuing clinical and pathologic confusion. Am. Heart J. 1991;121:942–947. DOI: 10.1016/0002-8703(91)90221-3

76. Nemickas R., Fishman D., Killip T. et al. Clinical pathologic conference: massive myocardial necrosis in a young woman. Am. Heart J. 1978;95:766–774DOI: 10.1016/0002-8703(78)90509-4

77. Sobel B., Sagel S., McKeel D. Shock and death in a 43-year-old woman. Am. J. Med. 1985;79:245–252. DOI: 10.1016/0002-9343(85)90016-6

78. Fenoglio J.J. Jr., Ursell P.C., Kellogg C.F. et al. Diagnosis and classification of myocarditis by endomyocardial biopsy. N. Engl. J. Med. 1983;308:12–18. DOI: 10.1056/NEJM198301063080103

79. Quigley P.J., Richardson P.J., Meany B.T. et al. Long-term follow-up of acute myocarditis: correlation of ventricular function and outcome. Eur. Heart J. 1987;8:Suppl J:39-42.

80. Dec GW Jr., Palacios I.F., Fallon J.T. et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies: clinical features, histologic correlates, and clinical outcome. N. Engl. J. Med. 1985;312:885–890

81. McCarthy R.E., Boehmer J.P., Hruban R.H. et al. Long-term out-come of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N. Engl. J. Med. 2000;342:690–695. DOI: 10.1056/NEJM200003093421003

82. Rockman H.A., Adamson R.M., Dembitsky W.P. et al. Acute fulminant myocarditis: long-term follow-up after circulatory support with left ventricular assist device. Am. Heart J. 1991;121:922–926.

83. Chang A.C., Hanley F.L., Weindling S.N. et al. Left heart support with a ventricular assist device in an infant with acute myocarditis. Crit. Care Med. 1992;20:712–715.

84. Jett G.K., Miller A., Savino D., Gonwa T. Reversal of acute fulminant lymphocytic myocarditis with combined technology of OKT3 monoclonal antibody and mechanical circulatory support. J. Heart Lung. Transplant. 1992;11:733–738.

85. Yasu T., Murata S., Katsuki T. et al. Acutely severe myocarditis successfully treated by percutaneous cardiopulmonary support applied by a newly developed heparin-binding oxygenator and circuits. Jpn. Circ. J. 1997;61:1037–1042.

86. Grogan M., Redfi eld M.M., Bailey K.R et al. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 1995;26:80–84.

87. Mason J.W., O'Connell J.B., Herskowitz A. et al. A clinical trial of immunosuppressive therapy for myocarditis. N. Engl. J. Med. 1995;333:269–275.

88. Tschope C., Cooper L.T., Torre-Amione. G. & Van Linthout, S. Management of myocarditis-related cardiomyopathy in adults. Circ. Res. 2019;124:1568–1583. DOI: 10.1161/CIRCRESAHA.118.313578

89. Ammirati E., Cipriani M., Moro C. et al. Clinical Presentation and Out-come in a Contemporary Cohort of Patients with Acute Myocarditis: Multicenter Lombardy Registry. Circulation. 2018;138(11):1088– 1099. DOI: 10.1161/CIRCULATIONAHA.118.035319

90. Ho J.S., Sia C.H., Chan M.Y., Lin W., Wong R.C. Coronavirus-induced myocarditis:

91. A meta-summary of cases. Heart Lung. 2020;49(6):681–5. DOI: 10.1016/j.hrtlng.2020.08.013

92. Shah S., Danda D., Kavadichanda C. et al. Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. Rheumatol. Int. 2020;40(10):1539–1554. DOI: 10.1007/s00296-020-04639-9

93. Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123–132. DOI: 10.14412/1995-4484-2020-123-132

94. Musikantow D.R., Turagam M.K., Sartori S. et al. Atrial Fibrillation in Patients Hospitalized With COVID-19: Incidence, Predictors, Outcomes, and Comparison to Influenza. JACC Clin Electrophysiol. 2021;7(9):1120–1130. DOI: 10.1016/j.jacep.2021.02.009

95. Ukimura A., Izumi T., Matsumori A. Clinical research committee on myocarditis associated with 2009 infl uenza A (H1N1) pandemic in Japan organized by Japanese circulation Society. A national survey on myocarditis associated with the 2009 infl uenza A (H1N1) pandemic in Japan. Circ. J. 2010;74(10):2193–9. DOI: 10.1253/circj.cj-10-0452

96. Guo T., Fan Y., Chen M. et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818. DOI: 10.1001/jamacardio.2020.1017

97. Raman B., Cassar M.P., Tunnicliffe E.M. et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. E. Clinical. Medicine. 2021;31:100683. DOI: 10.1016/j.eclinm.2020.100683